Exclusive: The secret to designing protein drugs with AI? Generate believes it's cryo-EM at unprecedented scale
One of the leading biotech companies using artificial intelligence to design protein-based drugs is betting that success lies not in more computing power, but in generating new laboratory data to feed back into its algorithms.
To gain that edge, Generate:Biomedicines has invested more than $30 million in a newly refurbished lab in Andover, MA, including nearly $15 million on four high-powered cryogenic electron microscopes — a quantity practically unheard of for the pricey tools.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.